Drugs / Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01086657 | Feb 2010 → Dec 2011 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01086657 ↗ |
| Modality | Vaccine | “The inactivated H5N1 vaccine is monovalent subunit virion vaccine, A/Indonesia/05/2005 clade 2, manufactured by Sanofi Pasteur, Inc (Swiftwater, PA).” NCT01086657 ↗ |
| Route | Intramuscular | “Each vaccination will be administered intramuscularly (IM) in the deltoid muscle using needle and syringe for the H5N1 vaccine and the Biojector 2000 Needle-Free Injection...” NCT01086657 ↗ |